Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830 is registered in ClinicalTrials.gov with Intellia Therapeutics as lead sponsor.

NCT NCT05120830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05120830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Lead sponsor
Intellia Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 10, 2021
Completion date
May 31, 2027
Enrollment
37 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema